Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CurveBeam AIASX:CVB Cash Ratio is 0.53 as of Dec. 2025, which is 24% below its 10-year median of 0.70. The stock has 5 warning signs investors should review. Among 841 Medical Devices & Instruments companies, CurveBeam AI ranks worse than 67.42% on this metric.
CurveBeam AI has a Cash Ratio of 0.53. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for CurveBeam AI's Cash Ratio or its related term are showing as below:
ASX:CVB'
s Cash Ratio Range Over the Past 10 Years
Min: 0.13 Med: 0.7 Max: 1.45
Current: 0.53
During the past 5 years, CurveBeam AI's highest Cash Ratio was 1.45. The lowest was 0.13. And the median was 0.70.
ASX:CVB's Cash Ratio is ranked worse than 67.42% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs ASX:CVB: 0.53
CurveBeam AI (ASX:CVB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
CurveBeam AI Cash Ratio Related Terms
CurveBeam AI Cash Ratio Historical Data
* Premium members only.
The historical data trend for CurveBeam AI's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CurveBeam AI's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CurveBeam AI Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's Cash Ratio distribution charts can be found below:
* The bar in red indicates where CurveBeam AI's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CurveBeam AI (ASX:CVB) has a Cash Ratio of 0.53 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on CurveBeam AI and its competitors. This is 24% below median its historical median of 0.70. Over the past decade, CurveBeam AI's Cash Ratio has ranged from 0.13 to 1.45. According to the industry distribution chart, CurveBeam AI ranks #567 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 67.4%.
Is CurveBeam AI's Cash Ratio too high?
CurveBeam AI's current Cash Ratio of 0.53 is 24% below median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 1.45. The Medical Devices & Instruments industry median Cash Ratio is 0.97. CurveBeam AI's value of 0.53 is 45.4% below this industry median. Based on the distribution chart, CurveBeam AI ranks #567 out of 841 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does CurveBeam AI's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #567 out of 841 companies for Cash Ratio. This places CurveBeam AI in the lower half of its industry. The industry median Cash Ratio is 0.97. CurveBeam AI's value of 0.53 is 45.4% below this benchmark. Historically, CurveBeam AI's own Cash Ratio has ranged from 0.13 to 1.45 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 0.97, CurveBeam AI has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CurveBeam AI's current Cash Ratio of 0.53 is 45.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on CurveBeam AI and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current Cash Ratio is 0.53, which is 24% below median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current Cash Ratio of 0.53. The current Cash Ratio is 0.53, which is 24% below median its 10-year median of 0.70 and 45.4% below the Medical Devices & Instruments industry median of 0.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current Cash Ratio is 0.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CVB has been successfully added to your 
